Shenouda Maged 4
4 · RELMADA THERAPEUTICS, INC. · Filed Jan 31, 2024
Insider Transaction Report
Form 4
Shenouda Maged
Chief Financial Officer
Transactions
- Purchase
Common Stock
2024-01-30$3.89/sh+15,000$58,323→ 28,028 total - Purchase
Common Stock
2024-01-29$3.65/sh+10,800$39,450→ 13,028 total - Purchase
Common Stock
2024-01-31$4.06/sh+6,875$27,943→ 34,903 total
Footnotes (4)
- [F1]The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
- [F2]Purchase prices range from $3.57 to $3.745 per share, inclusive.
- [F3]Purchase prices range from $3.82 to $3.90 per share, inclusive.
- [F4]Purchase prices range from $3.95 to $4.18 per share, inclusive.